The innate immune response to pneumococcal lung infection: The untold story

Trends in Immunology

Volumn 25, Issue 3, 2004, Pages 143-149

  Kadioglu, Aras ^a   Andrew, Peter W ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR;

ANTIGEN SPECIFICITY; BACTERIAL VIRULENCE; COMPLEMENT ACTIVATION; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG INFECTION; MOLECULAR INTERACTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTE; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE;

EID: 1342281657     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.12.006     Document Type: Review

References (53)

1. Mitchell T.J., et al. Molecular analysis of virulence factors of Streptococcus pneumoniae. J. Appl. Bacteriol. 26:1997;625-715.
2. Paton J.C., et al. Molecular analysis of the pathogenicity of Streptococcus pneumoniae. Annu. Rev. Microbiol. 47:1993;89-115.
3. Obaro S.K., et al. The pneumococcal problem. BMJ. 312:1996;1521-1525.
4. Tuomanen E.I. The biology of pneumococcal infection. Pediatr. Res. 42:1997;253-258.
5. Catterall J.R. Streptococcus pneumoniae. Thorax. 54:1999;929-937.
6. Mitchell, T.J. (1997) Pneumolysin: structure, function and role in disease. The comprehensive sourcebook of bacterial protein toxins. (26, 476-495) Academic press.
7. Tuomanen E.I. Molecular and cellular biology of pneumococcal infection. Curr. Opin. Microbiol. 2:1999;35-39.
8. Hollingshead S.K., Briles D.E. Streptococcus pneumoniae: new tools for an old pathogen. Curr. Opin. Microbiol. 4:2001;71-77.
9. Jarva H., et al. Complement resistance mechanisms of streptococci. Mol. Immunol. 40:2003;95-107.
10. Wright A.E., Douglas S.R. An experimental investigation of blood fluids in connection with phagocytosis. Proc. R. Soc. Lond. B. Biol. Sci. 72:1903;357-370.
11. Alper C.A., et al. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N. Engl. J. Med. 282:1970;350-354.
12. Gross G.N., et al. The effect of complement depletion on lung clearance of bacteria. J. Clin. Invest. 62:1978;373-378.
13. Sampson H.A., et al. Recurrent pyogenic infections in individuals with absence of the second component of complement. J. Clin. Immunol. 2:1982;39-45.
14. Mold C., et al. Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fcγ receptors. J. Immunol. 168:2002;6375-6381.
15. Walport M.J. Complement. N. Engl. J. Med. 344:2001;1058-1066.
16. Brown J.S., et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc. Natl. Acad. Sci. U. S. A. 99:2002;16969-16974.
17. Xu Y., et al. Complement activation in factor D-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14577-14582.
18. Van Emmerik L.C., et al. Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clin. Exp. Immunol. 97:1994;411-416.
19. Roy S., et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet. 359:2002;1569-1573.
20. Fearon D.T., Carroll M.C. Regulation of B lymphocyte responses to foreign and self antigens by the CD19-CD21 complex. Annu. Rev. Immunol. 18:2000;393-422.
21. Heyman B., et al. In vivo inhibition of the antibody response to a complement receptor specific monoclonal antibody. J. Exp. Med. 172:1990;665-668.
22. Thyphronitis G., et al. Modulation of mouse complement receptors 1 and 2 suppress antibody responses in vivo. J. Immunol. 147:1991;224-230.
23. Haas K.M., et al. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity. 17:2002;713-723.
24. Wright J.R. Immunomodulatory functions of surfactant. Physiol. Rev. 77:1997;931-962.
25. Holmskov U. Lung surfactant proteins (Sp-A and SP-D) in non-adaptive host responses to infection. J. Leukoc. Biol. 66:1999;747-752.
26. Crouch E., et al. Collectins and pulmonary innate immunity. Immunol. Rev. 173:2000;52-65.
27. Lawson P.R., Reid K.B.M. The roles of surfactant proteins A and D in innate immunity. Immunol. Rev. 173:2000;66-78.
28. Crouch E., et al. Molecular structure of pulmonary surfactant D (SP-D). J. Biol. Chem. 269:1994;17311-17319.
29. Matsushita M., Fujita T. The role of ficolins in innate immunity. Immunobiology. 205:2002;490-497.
30. Lim B.L., et al. Expression of the carbohydrate recognition domains of lung surfactant protein D and demonstration of its binding to lipopolysaccharides of Gram-negative bacteria. Biochem. Biophys. Res. Commun. 202:1994;1674-1680.
31. Kishore U., et al. The α-helical neck region of human lung surfactant protein D is essential for the binding of the carbohydrate recognition domains to lipopolysaccharides and phospholipids. Biochem. J. 318:1996;505-511.
32. Hartshorn K.L., et al. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am. J. Physiol. 274:1998;L958-L969.
33. Jounblat, R. et al. Binding and agglutination of Streptococcus pneumoniae by human surfactant protein D (SP-D) varies between strains but SP-D fails to enhance killing by neutrophils. Infect. Immun. (in press).
34. Kuan S.F., et al. Interactions of surfactant protein D with bacterial lipopolysaccharides: surfactant protein D is an Escherichia coli binding protein in bronchoalveolar lavage. J. Clin. Invest. 90:1992;97-106.
35. Madan T., et al. Binding of pulmonary surfactant Sp-A and SP-D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect. Immun. 65:1997;3171-3179.
36. LeVine A.M., et al. Distinct effects of surfactant protein A and D deficiency during bacterial infection on the lung. J. Immunol. 165:2000;3934-3940.
37. LeVine A.M., et al. Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J. Immunol. 167:2001;5868-5873.
38. Crouch E.C., et al. Interactions of pulmonary surfactant protein D (SP-D) with human blood leukocytes. Am. J. Respir. Cell Mol. Biol. 12:1995;410-415.
39. Botas C., et al. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11869-11874.
40. Clark H., et al. Surfactant protein D reduces alveolar macrophage apoptosis in vivo. J. Immunol. 169:2002;2892-2899.
41. Eggleton P., Reid K.B.M. Lung surfactant involved in innate immunity. Curr. Opin. Immunol. 11:1999;28-33.
42. Kadioglu A., et al. The host cellular immune response to pneumococcal lung infection in mice. Infect. Immun. 68:2000;492-501.
43. Jounblat R., et al. Pneumococcal behaviour and host responses during bronchopneumonia are affected differently by the cytolytic and complement activating activities of pneumolysin. Infect. Immun. 71:2003;1813-1819.
44. Kadioglu, A. et al. CD4 T lymphocyte interactions with pneumolysin and pneumococci suggests a crucial protective role in the host response to pneumococcal infection. Infect. Immun. (in press).
45. Wu Z.Q., et al. The mechanism underlying T cell help for induction of an antigen-specific in vivo humoral immune response to intact Streptococcus pneumoniae is dependent on the type of antigen. J. Immunol. 168:2002;5551-5557.
46. Snapper C.M., et al. Distinct types of T-cell help for the induction of a humoral immune response to Streptococcus pneumoniae. Trends Immunol. 22:2001;308-311.
47. Rubins J.B., Pomeroy C. Role of γ interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect. Immun. 65:1997;2975-2977.
48. Haraguchi S., et al. Interleukin 12 deficiency associated with recurrent infections. Proc. Natl. Acad. Sci. U. S. A. 95:1998;13125-13129.
49. Kemp K., et al. Pneumococcal infections in humans are associated with increased apoptosis and trafficking of type 1 cytokine-producing T cells. Infect. Immun. 70:2002;5019-5025.
50. Khan A.Q., et al. Endogenous pro and anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus pneumoniae. Infect. Immun. 70:2002;749-761.
51. Yoshimura A., et al. Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163:1999;1-5.
52. Malley R., et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. U. S. A. 100:2003;1966-1971.
53. Echchannaoui H., et al. Toll-like receptor 2-deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation. J. Infect. Dis. 186:2002;798-806.